Taken together, an AAV-mediated combination gene therapy that executes the silencing of Inhba and ACVR1R206H and ACVR1opt expression is a promising approach to suppress disabling HO, providing proof-of-concept for clinical translation to FOP patients. Here, HMOX1 is linked to fibrodysplasia ossificans progressiva.